Genomic profile, smoking, and response to anti-PD-1 therapy in non-small cell lung carcinoma. Academic Article uri icon

Overview

abstract

  • The recent successes of immune checkpoint therapies have established a new era for the treatment of patients with cancer, yet the predictors of response remain largely undetermined. We recently demonstrated that the genomic landscape of lung cancers substantially influences the response to programmed cell death 1 receptor (PD-1) blockade, providing new insights into the molecular determinants of the response to immunotherapy.

publication date

  • May 26, 2015

Identity

PubMed Central ID

  • PMC4845184

Scopus Document Identifier

  • 84966455144

Digital Object Identifier (DOI)

  • 10.1080/23723556.2015.1048929

PubMed ID

  • 27308563

Additional Document Info

volume

  • 3

issue

  • 1